Oversight and Monitoring of Blood Safety in the United States

Busch, Michael P.; Chamberland, Mary E.; Epstein, Jay S.; Kleinman, Steven; Khabbaz, Rima F.; Nemo, George J.

doi:10.1159/000031079

Cited by 28 publications

(22 citation statements)

References 48 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each element plays a role in preventing ‘tainted’ units from entering the blood inventory. In addition, the Department of Health and Human Services has constructed a comprehensive safety vigilance system to address unknown and emerging infectious threats (Busch et al ., 1999). Blood provided through such a system should prove safe, and inspire public confidence.…”

supporting

confidence: 86%

Will blood transfusion ever be safe enough?*

Klein

2001

Transfusion Medicine

View full text Add to dashboard Cite

supporting

confidence: 86%

Will blood transfusion ever be safe enough?*

Klein

2001

Transfusion Medicine

View full text Add to dashboard Cite

“…This has contributed to raise additional concern about the safety of transfusion treatment of thalassaemia. However, the risk – if any – for transmission of vCJD by blood products is extremely small, with no cases detected to date in blood recipients [77]. …”

Section: Complications Of Blood Transfusion Therapy In Patients With mentioning

confidence: 99%

Benefits and Complications of Regular Blood Transfusion in Patients with Beta-Thalassaemia major

Prati

2000

Vox Sanguinis

View full text Add to dashboard Cite

Early and regular blood transfusion therapy in patients with homozygous β-thalassaemia decreases the complications of severe anaemia and prolongs survival. In the long term, however, the beneficial effects of transfusions are limited by the organ damage resulting from iron overload, a consequence of the body’s limited capacity to excrete iron, and by the complications of infection with blood-borne agents. Transfusion regimens for β-thalassaemia have changed substantially during the past four decades. In current protocols, pre-transfusion haemoglobin concentration should not exceed 95 g/l. This allows adequate control of anaemia, with a relatively low rate of iron accumulation. Although iron chelation therapy has successfully improved survival free from cardiac disease, thalassaemic patients continuously present new clinical challenges. In fact, the vast majority of them suffer from post-transfusion chronic hepatitis C, which is expected to significantly contribute to morbidity in the forthcoming years. Furthermore, recent studies demonstrated that thalassaemics are at high risk of acquiring several blood-borne viruses. The potential role of these multiple infections in inducing clinical disease is still uncertain, and needs to be thoroughly clarified in future surveys.

show abstract

“…Hemovigilance networks have been either introduced or reinforced in North America and Europe in the past few years. The organization of each network varies greatly from one country to another 1‐8 . This heterogeneity is related to the administrative organizations responsible for health systems in each country, as well as to the social and political perception of transfusion‐related risks.…”

mentioning

confidence: 99%

“…The aim of the network is to collect and evaluate information on unexpected or untoward effects related to blood components in order to prevent their recurrence. This organization differs from those where each step of the transfusion chain is treated separately, as in the United States and the United Kingdom 4‐6 . Moreover, reporting is mandatory, as opposed to the United Kingdom Serious Hazards Of Transfusions (SHOT) network, which works on a voluntary basis 4,5 …”

mentioning

confidence: 99%